ArticleMolecular therapy. Advances2026
Comparative pharmacokinetic derivations for axicabtagene ciloleucel and brexucabtagene autoleucel in the treatment of B cell malignancies.
Article in Molecular therapy. Advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Model-Based Analysis with Mechanistic Insights to CAR-T-Cell Therapy Kinetics: Case Study with Axicabtagene Ciloleucel and Brexucabtagene Autoleucel.Clinical pharmacology and therapeutics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Axicabtagene ciloleucel (axi-cel) and brexucabtagene autoleucel (brexu-cel) are autologous anti-CD19 chimeric antigen receptor (CAR) T cell products originally approved in the pivotal ZUMA-1 and ZUMA-2 clinical studies for the treatment of relapsed/refractory (r/r) large B cell lymphoma (r/r LBCL) and r/r mantle cell lymphoma (MCL), respectively. The pharmacokinetics (PKs) of axi-cel and brexu-cel are well characterized to associate with safety and efficacy. Methods for deriving molecular PKs to quantify CD19 CAR T cell levels in clinical trials and real-world settings vary widely, lack standardization, and often do not consistently account for cellular composition. This study evaluated three distinct PK derivation methods for axi-cel and brexu-cel, utilizing either quantitative polymerase chain reaction (qPCR) or droplet digital PCR (ddPCR), with corresponding units: (1) qPCR (CAR T cells/μL of blood), (2) ddPCR
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.